Bone was reported as a crucial organ for regulating glucose homeostasis. In this study, we found that Phex mutant mice (PUG), a model of human X-linked hypophosphatemic rickets (XLH), displayed metabolic abnormality in addition to abnormal phosphate homeostasis, skeletal deformity and growth retardation. Glucose tolerance was elevated with enhanced insulin sensitivity in PUG, though circulating insulin level decreased. Interestingly, bone mineral density defects and glucose metabolic abnormality were both rescued by adding phosphorus-and calcium-enriched supplements in daily diet. Serum insulin level, glucose tolerance and insulin sensitivity showed no differences between PUG and wild-type mice with rescued osteocalcin (OCN) following treatment. Our study suggested that OCN is a potential mediator between mineral homeostasis and glucose metabolism. This investigation brings a new perspective on glucose metabolism regulation through skeleton triggered mineral homeostasis and provides new clues in clinical therapeutics of potential metabolic disorders in XLH patients. glucose metabolism, mineral homeostasis, bone, Phex, X-linked hypophosphatemic rickets
X-linked hypophosphatemic rickets (XLH), also known as X-linked vitamin D-resistant rickets, is one of the rachitic bone diseases with an incidence rate of about 1 in 20,000 [1] . Patients with XLH usually show rickets in children and osteomalacia in adults. XLH is characterized by growth retardation, impaired phosphate reabsorption, affected bone mineralization, low level of 1,25-(OH) 2 D 3 and occasionally dental abscess [2, 3] . Most XLH patients possess various mutations on gene Phex [3, 4] , abbreviated for phosphate regulating gene with homologies to endopeptidases on the X chromosome, proving the importance of PHEX functions in skeletal morphology and mineral homeostasis [5, 6] .
In the past decades, bone was studied as an endocrinal organ [7, 8] . Interactions between bone and energy metabolism aroused extensive interests and concerns [911] . Phex is mainly expressed in osteoblasts and odontoblasts [1214] and its mutations lead to reduced 1,25-(OH) 2 D 3 and elevated circulating FGF23 (fibroblast growth factor 23) [1517]. 1,25-(OH) 2 D 3 and its receptor could influence expression of uncoupling protein (UCP) in adipocytes [18, 19] . In vitro studies demonstrate that the role of 1,25-(OH) 2 D 3 in lipid metabolism is regulator of peroxisome proliferator-activated receptor alpha (Ppara) [20] . Circulating FGF23 is also associated with fat mass and serum lipids [21] . In mouse models of XLH, like Hyp mice, decreased renal glucose reabsorption activity [22] , increased glucose production in renal proximal tubules [23] and osteoblasts [24] were observed. The only known physiological substrate of PHEX protein, acidic serine aspartate-rich MEPE associated motif (ASARM peptide), could regulate glucose metabolism and insulin signaling [14] . The above findings indicate PHEXmediated association between skeletal function and energy metabolism.
Furthermore, phosphate homeostasis, destructed in XLH patients [25] , is also connected to energy metabolism [26, 27] . Phosphorus contributes to bone development and maintenance [28] . Bone regulates energy metabolism through modifying expression of relative genes such as osteocalcin (Ocn). OCN is produced by osteoblasts and affects beta-cell functions. Overexpression of OCN resulted in aberrant insulin production and sensitivity [11, 29, 30] . All the reports above imply a mineral homeostasis-mediated correlation between mineral homeostasis, bone functions and energy metabolism.
This study presents a series of novel phenotypes in XLH mouse model and provides a new angle of view to study the relationship between skeletal deformities and glucose metabolism. We rescue the abnormal bone and glucose metabolism via modifying mineral homeostasis.
Materials and methods

Mice and diets
PUG mice were obtained from Model Animal Research Center (MARC) of Nanjing University (Nanjing, Jiangsu, China). All mice were bred in specific pathogen-free (SPF) animal rooms and manipulated according to Animal protocol approved by IACUC of MARC. Mice were housed under a normal 12 h light/12 h dark with water and food ad libitum. PUG male mice and their wild-type littermates were divided into three groups, the first was wild-type mice (WT) fed with regular diet (RD, 0.5% Pi and 0.5% Ca), the second was PUG fed with RD and the third was PUG fed with high Pi/Ca diet (HPD, 2% Pi and 1.1% Ca). All three groups were fed with respective diets from ablactation at postnatal 21 days.
Body weight and body length measurements
Body weights of all mice were measured once a week at 5:30 p.m. Whole tail lengths and body lengths were measured after anesthetization by 2.5% avertin (5 mg per 10 g body weight) [31] .
Bone mineral density (BMD) and X-ray imaging
Excluding head and tail, lean mass and bone mineral density were assessed by dual-energy X-ray absorptiometry (DEXA) system (PIXImus 2, GE lunar, USA). X-ray photos were taken using Faxitron MS-20 specimen radiography system (Faxitron X-ray Corporation, Wheeling, IL, USA) for 12 s at 23 kV. All mice were fasted overnight (16 h) and anesthetized by 2.5% avertin (5 mg per 10 g body weight) before measurements.
Blood biochemical analysis
Blood samples were collected from venous sinus of optical orbit after overnight fasting. Clot blood samples by standing for 2 h on ice and centrifuge them at 3,000×g for 20 min at 4°C to isolate the serum. Serum was store at 20°C for short period and 80°C for long storage. Serum phosphorus (Pi) , calcium (Ca) and alkaline phosphatase (ALP) were detected with the 7600 Clinical Analyzer (Hitachi High-Technologies, Japan).
Blood glucose, serum insulin and serum osteocalcin measurements
Blood glucose levels were tested in blood samples obtained from mice tail tips after fasting from 9:00 a.m. to 5:00 p.m. every week using glucocard blood glucose test meter (GT-1640, ARKRAY Inc, Japan). Mice blood was collected from venous sinus of optical orbit at 9:30 a.m. after fed ad lib or fast overnight for serum insulin level detection respectively. Serum insulin and osteocalcin levels were detected via RAT/MOUSE INSULIN ELISA KIT (Millipore, USA) and Mouse Osteocalcin EIA kit (Biomedical Technologies Inc., USA).
Glucose tolerance test and insulin tolerance test
Every two weeks, glucose tolerance test (GTT) or insulin tolerance test (ITT) was carried out after 8 and 6 h fasting in the daytime respectively. Mice were intraperitoneally injected with D-(+)-glucose (G6152, Sigma, USA; 2 g/kg body weight) for GTT and insulin (Novo Nordisk, Tianjing, China, 0.5 IU/kg body weight) for ITT. Blood glucose was detected from tail tips at 0, 15, 30, 45, 60, 90 and 120 min after injection.
Statistics
Statistical analyses were determined using unpaired twotailed student's t test. All data are expressed as mean±SEM. A P-value of less than 0.05 was considered statistically significant. * and §, P<0.05; ** and § §, P<0.01; *** and § § §, P<0.001.
Results
PUG mice show deficient skeletal morphology and abnormal mineral homeostasis
In different disease models of XLH, for instance, Hyp and Gy mice, they display a series of rickets associated phenotypes, such as growth retardation, skeletal anomalies and mineral deficiency [2, 32] . PUG mice, with a missense mutation on Phex, were reported as a mouse model of XLH [33] . To confirm the phenotype, we studied the growth sta-tus and skeletal development in PUG firstly. Concerning that Phex is located on X chromosome and female mice displayed randomized X chromosome inactivation, hemizygous male PUG mice were used for subsequent investigations.
PUG show lower body weight than wild-type mice at the age of weaning (WT: 18.96±0.24 g; PUG: 15.85±0.26 g) ( Figure 1A ). Contemporary whole body length was measured ( Figure 1B ) and PUG displayed shortened skeleton in early growth stage (WT: 7.64±0.05 cm; PUG: 5.72±0.06 cm). Bone mineral density (BMD) was decreased in both local (left femur) (WT: 0.072±0.0016 g cm 2 ; PUG:
0.053±0.0040 g cm 2 ) and systemic (WT: 0.057±0.0007 g cm 2 ; PUG: 0.051±0.0010 g cm 2 ) analysis ( Figure 1C ).
X-ray images of PUG lying on its side displayed stunted stature, shorter bone structure and increased curvature of spinal column ( Figure 1D ). Furthermore, we measured circulating inorganic phosphorus (Pi), calcium (Ca) and alkaline phosphatase (ALP) levels by analyzing serum of 3-week-old mice. We found out that PUG show decreased Pi levels (WT: 2.44±0.19 mmol L 1 ; PUG: 2.05±0.38 mmol L 1 ) ( Figure 1E ) and in- glucose and response to insulin, we performed glucose tolerance tests and insulin tolerance tests at 7 and 10 weeks of age, respectively. PUG mice showed significantly improved glu-cose tolerance than control mice ( Figure 2C ). Moreover, lower blood glucose levels after insulin administration were observed in PUG mice ( Figure 2D ). These suggested increased ability in disposing of glucose load and enhanced insulin sensitivity in PUG mice. Collectively, blood glucose clearance capacity and peripheral insulin sensitivity were improved in PUG mice compared to even-aged wild-type, suggesting altered glucose metabolism correlative to skeletal disorder.
Bone deformity and imbalanced mineral homeostasis were partially restored after high Pi/Ca diet treatment
Combined inorganic phosphorus and 1,25-(OH) 2 D 3 are used as therapeutic regimen to treat XLH patients [34, 35] . However, animal model research and human cases studies have demonstrated that XLH carriers are resistant to vitamin D therapy [36] . Therefore, we treated 3-week-old PUG with high Pi/Ca diet (HPD) containing 2% inorganic phosphorus and 1.1% calcium to check whether HPD could rescue retarded growth and defected bone development. Regular diet (RD) with 0.5% phosphorus and 0.5% calcium was used as control. Calcium was added to keep the balance between phosphorus and calcium and to avoid skeletal demineralization and mineral deposits in soft tissues [37, 38] . PUG mice were fed with HPD from the age of 3 weeks, with RD fed PUG and WT as controls. Body weights of three groups were measured once a week. After 9 weeks of HPD treatment, PUG gained significant heavier body weight than RD fed PUG ( Figure 3A) . Osteocalcin (OCN), produced and secreted solely by osteoblasts, is used as a biochemical marker to represent bone formation [39] . Serum OCN level declines as the age increases [40] . Elevation of circulating OCN levels was detected in 3-week-age PUG mice (WT: 188.2±11.1 ng mL 1 ; PUG: 250.7±12.6 ng mL 1 ), suggesting disordered skeletal development and altered energy metabolism ( Figure 3B ). After 5 weeks of treatment, HPD fed PUG displayed corrected serum osteocalcin (WT RD: 49.8±5.8 ng mL 1 ; PUG RD: 105.5±7.5 ng mL 1 ; PUG HPD: 56.1±13.7 ng mL 1 ) ( Figure 3B ).
Wild-type mice showed no difference in serum OCN level before and after HPD treatment ( Figure S1 in Supporting Information). After applying one year of high Pi/Ca diet, PUG acquired improved body length (WT RD: 9.54±0.06 cm; PUG RD: 7.85±0.15 cm; PUG HPD: 8.83±0.11 cm) ( Figure 3C ). In addition, bone mineral density and lean mass displayed notable raise ( Figure 3D and E). Circulating inorganic phosphorus ( Figure 3F ) and alkaline phosphatase ( Figure 3G ) were rescued after 2 weeks of HPD treatment and kept close to normal levels after long period treatment. These results show that skeletal deformity was rescued after restored mineral homeostasis through phosphorus and calcium supplementation.
Figure 3
Pi and Ca supplements partially rescued growth retardation and mineral deficiency of PUG mice. PUG mice were divided into two groups and were fed with regular diet (RD) and high Pi/Ca diet (HPD) respectively. Wild-type mice were fed with RD as control. A, Body weights of WT (n=8), RD fed PUG (n=7) and HPD fed PUG mice (n=6) were measured once a week during HPD treatment. B, 3-week-old RD fed WT (n=7) and PUG (n=5) were used to detect total OCN levels. Six pairs of WT and PUG mice were fed with HPD. RD fed wild-type mice (n=7) were used as control. After 5 weeks of Pi and Ca supplementation, total osteocalcin (OCN) levels were detected. (C) Whole body length, (D) bone mineral density of left femur and (E) lean mass were detected in yearling WT (n=8), RD PUG (n=6) and HPD PUG mice (n=4). Blood biochemistry tests were conducted by testing mouse serum to detect circulating (F) inorganic phosphorus (Pi) and (G) alkaline phosphatase (ALP) levels at 5 weeks of age (WT, n=8; RD PUG, n=8; HPD PUG, n=6) and 1-year-old (WT, n=8; RD PUG, n=6; HPD PUG, n=6). Data are expressed as mean±SEM. *, P<0.05; **, P<0.01; ***, P<0.001.
Rescued glucose metabolism in high Pi/Ca diet treated PUG mice
We have described affected glucose metabolism in PUG mice and demonstrated that mineral supplements prevent growth retardation and bone deformity. We inquired about whether the altered glucose homeostasis was engendered by hypophosphatemia, so we examined fasting insulin levels in HPD fed PUG mice. As shown in Figure 4A , serum insulin levels returned to normal levels (WT RD: 0.54±0.06 ng mL 1 ; PUG RD: 0.39±0.08 ng mL 1 ; PUG HPD: 0.53±0.07 ng mL 1 ) after 5 weeks of treatment. We performed GTT and ITT 2 weeks later. It shows that PUG obtained normalized peripheral insulin sensitivity ( Figure 4B ) after feeding HPD for 7 weeks. Simultaneously, glucose clearance capacity was restored ( Figure 4C ). The area under curve of GTT represented approximate glucose tolerance ability between PUG and wild-type mice (WT RD: 253.6±14.6; PUG RD: 207.6±12.7; PUG HPD: 239.0±13.6) ( Figure 4D) . The above findings together demonstrated that glucose metabolism was rescued after phosphorus and calcium supplementation and suggested that mineral homeostasis affects glucose homeostasis in skeletal disorder. 
Discussion
Regulation of energy metabolism by bone has long been discussed. In this study, phex mutation induced not only defected bone development but also altered glucose metabolism. We described enhanced glucose tolerance and insulin sensitivity associated with bone deformities and disordered mineral metabolism for the first time in animal model of XLH. In addition, we rescued both skeletal and metabolic abnormalities via restoring mineral homeostasis, suggesting a close correlation between bone and energy metabolism. Normalized glucose cleaning capability and peripheral insulin sensitivity, following restored serum phosphorus level, demonstrate that mineral homeostasis plays an important role in regulation of glucose metabolism by bone. We also discovered decreased blood glucose in XLH mouse model. Blood glucose is regulated by G6Pase in the liver. Elevated hepatic G6Pase activity brings about enhanced glyconeogenesis and glycogenolysis, leading to serum glucose elevation [41] . However, another study reported that glucose-6-phosphatase (G6Pase) activity was increased in both XLH mouse model and phosphate-deprived mice [42] . We did not measure G6Pase activity in PUG mice. If hepatic G6Pase activity was upregulated, we speculated the reason might be a feedback effect aiming to reverse the abnormal glucose metabolism according to published reports [43] . Moreover, blood glucose homeostasis could be regulated by other different signaling. Several studies show that blood glucose could be modulated by intestine G6PC activity [44] , glucose transportation [43] and glucose uptake [45] , resulting in irrelevance between plasma glucose level and hepatic G6Pase activity. In XLH mouse model, decreased renal glucose reabsorption activity is also considered contributory to the decreased blood glucose [22] . Otherwise the reduced blood glucose of PUG mice resulted from abnormal glucose transport and oxidation stimulated by OCN [45] .
Osteocalcin (OCN), which is secreted by the bone, is one of the mediators communicating with adipose [46, 47] . OCN is also used as a biomarker of skeletal development, and increased serum OCN level is associated with increased bone mineral density during osteoporosis treatment [48, 49] . However, in our study, elevated OCN levels were accompanied by decreased BMD. This result might be attributed to retarded growth and deficient glucose metabolism [50, 51] . Several researches declare that BMD and osteocalcin level can be influenced by estrogen, calcium and fat mass, resulting in decreased BMD and increased osteocalcin level [52, 53] . It may explain the contradiction between BMD decline and serum OCN level elevation in PUG mice.
OCN is also involved in glucose metabolism via increasing adiponectin in mice [54] . Importantly, uncarboxylated form of OCN promotes insulin secretion to affect glucose metabolism by means of stimulating glucagons-like peptide-1 (GLP-1) [55] . OCN circulation can be attenuated by dietary phosphorus supplementation [56] , implying functions of phosphorus in regulating OCN secretion and function. Of note, our work revealed restored OCN levels and insulin levels after mineral homeostasis recovery in PUG mice, followed by restored glucose tolerance and insulin sensitivity. Overall, there may be a mechanism in which aberrant phosphate homeostasis aroused by bone dysfunction regulates glucose metabolism through regulating circulating OCN level.
Bone is regulated by adipose-secreted leptin which acts on the osteoblast endocrine cell to inhibit bone formation through hypothalamic and sympathetic nervous system relays [5760]. On the other hand, OCN secretion is facilitated by bone to regulate adiposity, glucose metabolism, and insulin sensitivity in turn [6163] . Ocn-deficient mice exert not only mildly increased bone mass but also lessened β-cell proliferation, glucose intolerance and insulin resistant phenotypes, imitating type II diabetes [29, 64] . Correlations between circulating OCN levels and β-cell functions or glucose metabolism were observed in obese adults and type II diabetes patients [65, 66] , suggesting secretion role of skeleton in regulating lipid anabolism and catabolism. Adiponectin secretion was accelerated by OCN [45] while serum OCN level was positively correlated with adiponectin receptor 1 (AdipoR1) expression [67] , developing a feedback loop between osseous tissue and energy metabolism [68, 69] . Therefore, OCN elevation in XLH disease is probable to exhibit damaged lipid metabolism. It highlights new arenas for potential investigation in skeletal regulation of energy metabolism.
In summary, our findings represent significant progress in understanding the mechanism that bone affects energy metabolism through regulating mineral homeostasis. OCN could be a potential target for rickets and metabolic diseases treatment in the future. Though more efforts should be made to identify how OCN functions as a mediator between PHEX and mineral homeostasis. Additionally, further exploration is needed to clarify how Phex mutation brings about imbalanced phosphorus homeostasis. 
